LifeSci Advisors Announces 12th Board Appointment Through Its Board Placement Initiative
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, today announces the 12th appointment of a female executive to a life sciences company board as part of its Board Placement Initiative (BPI). LifeSci Advisors launched BPI in the summer of 2016 with the goal of connecting female executives in the life sciences industry with companies looking for board candidates.
LifeSci is pleased to share that Dr. Carol L. Brosgart has joined the Board of Directors of ABIVAX, a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer. Dr. Brosgart is a Clinical Professor of Medicine, Epidemiology and Biostatistics at the Institute for Global Health, Department of Medicine, University of California in San Francisco, CA.
"I am pleased to join the board of ABIVAX and help this progressive company continue to advance their clinical pipeline forward," said Dr. Brosgart. "I look forward to contributing to the strategic and clinical development oversight of the company, and I am thankful to LifeSci for facilitating this placement."
Dr. Brosgart has served as an independent director on the Boards of both public and privately-held biotechnology companies, as a member of the Federal US CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment, and was the Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC. She has held numerous senior management positions within biotechnology and health care. Dr. Brosgart was the Chief Medical Officer for Alios BioPharma (now Johnson & Johnson), a biotech company developing therapies to treat viral diseases. Dr. Brosgart joined Alios from Children's Hospital & Research Center in Oakland, California, where she served as Senior Vice President and Chief Medical Officer. For eleven years Dr. Brosgart held a number of senior management positions at Gilead Sciences. While Vice President of Clinical Research at Gilead she was responsible for the clinical development and approval by the FDA and by regulatory authorities worldwide of two antiviral therapies - Viread® for the treatment of HIV, and Hepsera® for the treatment of chronic hepatitis B.
Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, clinical care, research, and teaching. She was among the first physicians in the United States to recognize and treat patients with HIV/AIDS. Dr. Brosgart was the founding Medical Director of the East Bay AIDS Center. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development, and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV. Dr. Brosgart received her B.S. in community medicine from the University of California, Berkeley (UCB), her M.D. from the University of California, San Francisco (UCSF), and her residency training in Pediatrics (UCSF) and Public Health and Preventive Medicine (UCB). She has published extensively in the areas of infectious diseases, focusing on antiviral therapy for HIV, HBV, CMV and related public health policy.
"We are confident that Carol's insights and experience will be a huge asset to ABIVAX as they continue to develop their clinical programs," said Michael Rice, President and Co-Founder, LifeSci Advisors. "We're very happy to have made the introduction and look forward to announcing more successful appointments through our Board Placement Initiative in the near future."
"We are thrilled that Carol is bringing her expertise and deep industry knowledge to our board," said Dr. Hartmut J. Ehrlich, Chief Executive Officer, ABIVAX. "Her vast wealth of experience and passion for treating patients with HIV/AIDS will be invaluable to the company's clinical strategy, and we are pleased to have found Dr. Brosgart through LifeSci's Board Placement Initiative."
LifeSci Advisors' Board Placement Initiative (BPI) was launched with the goal of helping companies in the life sciences industry diversify and strengthen their company boards. Introductions between companies and eligible board candidates are made after LifeSci has met with a company's management team or Board regarding the skills and expertise they are seeking in a candidate, and after the LifeSci team has properly vetted the board candidates. BPI now has helped to place 12 women on corporate boards and is looking to continue this success. With a proprietary network comprised of board-ready women, LifeSci Advisors hopes that BPI can become a valuable platform where both female executives and life sciences companies are able to network and to grow.
BPI is accepting resumes from interested candidates and referrals on an on-going basis. To find out how you can use the BPI network for your next board candidate search, visit www.lifesciadvisors.com/board-diversity-initiatives. Inquiries, resume submissions, and open board seat referrals can be sent to firstname.lastname@example.org.
LifeSci Advisors, LLC (www.lifesciadvisors.com) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci's team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.
LifeSci Partners (www.lifescipartners.com) is the leading provider of consulting services in the areas of investor relations, public relations, corporate communications and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, LifeSci Partners delivers unparalleled services to life sciences companies globally.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Nasdaq Welcomes Dropbox, Inc. (Nasdaq: DBX) to The Nasdaq Stock Market23.3.2018 19:52 | Pressmeddelande
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Dropbox, Inc. (Nasdaq:DBX), a leading global collaboration platform, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Founded in 2007, Dropbox serves more than 500 million registered users across 180 countries. Over the past decade, Dropbox has pioneered the worldwide adoption of file sync and share software and has expanded its product capabilities to help users do their best work. Today, 80% of its 11 million paying customers use Dropbox for work. "Today we're taking an important step in our journey. I'm so grateful to all of our customers and our incredible team for getting us here," said Drew Houston, Co-Founder and Chief Executive Officer. "Nasdaq has always championed innovation and entrepreneurship, and we're thrilled to partner with them as we become a public company." "For more than a decade, Dropbox has transformed how people around the world access
Barings Alternative Investments Expands Aviation Investment Platform Through Partnership with Genesis Aircraft Services23.3.2018 15:00 | Pressmeddelande
CHARLOTTE, N.C., March 23, 2018 (GLOBE NEWSWIRE) -- Barings Alternative Investments, part of Barings LLC, one of the world's leading financial services firms, announced today the expansion of its aircraft leasing platform on behalf of the firm's institutional fund clients through Genesis Aircraft Services Limited. To facilitate new aircraft acquisitions on behalf of Barings' clients, Genesis will increase existing capabilities to now include all commercial, technical, portfolio and legal management functions required of a full-service premier owner and lessor of commercial aircraft. As part of its increased capabilities, Karl Griffin will join Genesis as Chief Commercial & Investment Officer and will also be appointed to the Genesis Board of Directors effective May 2018; Anna Reimers will join Genesis as Chief Legal Officer; and John McMahon will be appointed to Genesis' Board as an independent director. Griffin is currently the Chief Operating Officer at DAE Capital, an aircraft leasi
Agrisolutions Acquires Trinity23.3.2018 12:00 | Pressmeddelande
HAMILTON, Ontario, March 23, 2018 (GLOBE NEWSWIRE) -- Venanpri Group's Agrisolutions division, which services the global agricultural marketplace with its Ingersoll and Bellota brands, announced today the acquisition of Trinity Logistics Corporation ("Trinity"). Based in the U.S., Trinity provides supply-chain solutions relating to fasteners and other components to leading global OEMs that produce mission critical machinery for the agricultural and construction end markets. The terms of the transaction were not disclosed. Headquartered in Davenport, Iowa, Trinity has established ten strategically located service facilities throughout the United States. Trinity specializes in the supply of standard and custom components through vendor managed inventory programs and other arrangements tailored to customer needs. Trinity utilizes its industry leading technology to improve the flow of products, services and information across the supply chain resulting in excellence in the operations of it
BIMobject AB: BIMobject releases toolkit to help digitalise the construction industry23.3.2018 10:57 | Pressmeddelande
BIMobject releases a toolkit for easy, seamless integration of BIM-softwares with the corporation's cloud-based platform, which hosts digital building products. This gives building product manufacturers more marketing channels and easier access to the platform's user base. BIMobject's new Software Development Kit (SDK) is a quick, efficient way for third party-developers to start using the BIMobject platform. It allows for BIMobject's market-leading platform for digital building products easily to be integrated in different BIM-programmes, such as apps. The design, user experience, and features can be defined entirely by the developer. The SDK is made available as an open source-code for free download and is connected to the web interface upon application. The code is freestanding, making it independent of updates. This in turn makes the SDK future-proof, easy to apply, and less vulnerable, with reduced loading time of the integrated digital content. For more information, please contac
BIMobject AB: BIMobject släpper startkit som hjälper byggbranschen att digitaliseras23.3.2018 10:57 | Pressmeddelande
BIMobject släpper ett startkit som gör det enkelt att skapa sömlös integration av BIM-programvaror med bolagets molnbaserade plattform BIMobject Cloud för digitala byggprodukter. Produkttillverkare ges på så vis fler marknadsföringskanaler och smidigare tillgång till plattformens användarbas. BIMobjects nya Software Development Kit (SDK) gör det enkelt för tredjepartsutvecklare att snabbt börja använda bolagets webbgränssnitt. Innehållet som tillhandahålls på BIMobjects marknadsledande plattform för digitala byggprodukter kan på så vis enkelt integreras i olika BIM-program, exempelvis i form av appar. Design, användarupplevelse och funktioner kan bestämmas helt av utvecklaren. Startkitet tillhandahålls som öppen källkod ("open-source") för gratis nedladdning och kopplas till webbgränssnittet efter ansökan. Koden i startkitet är fristående och därför oberoende av uppdateringar. Detta gör startkitet framtidssäkert, lättapplicerat, mindre sårbart och kortar dessutom ned laddningstider av
Comodo CA Sees 35 Percent Year-Over-Year Increase in EV Certificates22.3.2018 15:47 | Pressmeddelande
EV SSL will be a topic of discussion at the Comodo CA booth during RSA 2018 CLIFTON, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, will address evolving cyberthreats and the increasing importance Extended Validation (EV) TLS/SSL certificates play in securing websites and inspiring consumer trust at the RSA Conference 2018, San Francisco, April 16 - 20. According to the Feb 2018 Netcraft report, Comodo CA has seen a 35 percent year-over-year increase of EV certificate units* making it one of the fastest growing providers of high assurance certificates. The volume of EV certificates globally also saw a record year in 2017 as more and more businesses adopt EV as standard practice for their websites. The demand for stronger, more secure EV certificates comes in the wake of increased phishing websites using Domain Validated (DV) certificates. Phishing websites imitate legitimate websites to steal customers' funds and identities. Phishi
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum